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Abstract: In drug discovery, most small molecules cannot cross many stages, only a few can become drug candidates. Once the drug
molecule is approved and marketed, nontarget effects that are not easily distinguishable from the actual target of the drugs might be
evaluated. This situation restricts the treatment. Thus, the discovery of new drugs is a very long and expensive process. In recent years,
without developing new drugs, the approach of using different and new target molecules in new indications apart from the indications
of licensed drug molecules has gained importance.
In this study, using the connectivity map program, it was determined that metformin and tolbutamide used in the treatment of type II
diabetes had the potential to inhibit Rho kinase. In the experimental results to confirm this data, it has been shown that metformin and
tolbutamide decrease the cell area within 24 h and metformin inhibits the activation of Rho kinase in MCF-7 cells.
These results indicate that metformin, which is used in the treatment of type II diabetes, acts as a ROCK inhibitor. Metformin has potential in the treatment of various pathological conditions in which Rho kinase has a role.
Key words: Connectivity MAP, Rho kinase, metformin, off-target effect, oral antidiabetics

1. Introduction
Identifying drug targets for the treatment of diseases and
developing new compounds that can induce the desired
effect through drug-target interaction is a very long and
expensive process for researchers. In recent years, apart
from the indications for the approved drug molecules, the
approach of using these drugs in different indications by
identifying different and new target molecules has gained
importance. Thus recently, in silico pattern-matching,
software are widely used to identify new targets for small
molecules.
The connectivity map (CMAP) program is a webbased library that is produced by the Broad Institute
(Cambridge, MA, USA). CMAP includes 1.5 million gene
expression profiles from various cell lines (A375, A549,
HCC515, HEPG2, HT29, MCF7, PC3, HA1E, VCAP)
that were treated with ~ 5000 small molecule compounds
(Lamb et al., 2006). The software is a catalog comparing
the similarities of changes at the gene expression level
induced by small molecules, and scoring the similarity.
In 1996, Rho kinase (ROCK) was identified as the
downstream effector of Rho A, which mediates many
intracellular signaling mechanisms (Kimura et al.,
1996; Nakagawa et al., 1996; Ark et al., 2010; Özdemir

et al., 2016). ROCK has two different isoforms: ROCK I
(p160ROCK, ROKβ) and ROCK II (ROKα) (Kimura et
al., 1996; Nakagawa et al., 1996). Inhibition of Rho kinases
affects the function of many downstream substrates, such
as the myosin binding subunit of myosin light chain
phosphatase (MLCP), myosin light chain (MLC), LIMK
kinases (LIM kinases 1 and 2), myristoylated alaninerich C-kinase (MARCKS), collapsing response mediator
protein-2 (CRMP2), adducin, sodium/hydrogen exchanger
1 (NHE1) and ezrin-radixin-moesin (ERM) (Riento and
Ridley, 2003). Rho kinase inhibitors have a potential
therapeutic efficacy in a wide range of pathological
conditions, such as asthma (Schaafsma et al., 2008), cancer
(Rath and Olson, 2012), erectile dysfunction (Albersen et
al., 2010), glaucoma (Olson, 2008), insulin resistance (Lee
et al., 2009), kidney failure (Komers et al., 2011), neuronal
degeneration (Mueller et al., 2005) and osteoporosis
(Olson, 2008). However, only two ROCK inhibitors have
been approved for the treatment of diseases. Fasudil, the
Rho kinase inhibitor, was first approved in 1995 for the
treatment of cerebral vasospasm in Japan and China (Bito
et al., 2000). Ripasudil, another Rho kinase inhibitor, was
approved for use in glaucoma treatment in Japan in 2014
(Garnock-Jones, 2014).
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Several studies showed that oral antidiabetic drugs
might have a clinical use on various diseases other than
the use of type II diabetes. For instance, metformin, one
of the oral antidiabetic drugs, has been reported in the
treatment of polycystic ovary syndrome (PCOS) in which
hyperinsulinaemia is accompanied (Diamanti et al., 2010).
Additionally, metformin inhibited the proliferation of
cancer cells in different cancers, such as ovarian, melanoma,
prostate, and breast cancers (Saraei et al., 2019). Another
group of drugs used in the treatment of diabetes are
sodium glucose cotransporter 2 (SGLT2) inhibitors. These
drugs also show cardiovascular and renal protective effects
through the reduction of preload by diuretic effect and the
reduction of afterload by lowering blood pressure (Lytvyn
et al., 2017). These pleiotropic on-target effects pointed out
that the potential off-target effect of oral antidiabetic drugs
might be effective in different pathological conditions.
The aim of this study was to identify an off-target of
FDA-approved oral antidiabetic drugs that might be
potential candidates as ROCK inhibitor using connectivity
map.

the cells reached 70%–80 % confluency, they were counted
and the specified number of cells were seeded in petri
dishes.

2. Materials and methods

2.4. Holographic 3D cell analysis
HeLa and MCF-7 cells were cultured in 35-mm dish (Ibidi
GmbH, Gräfelfing, Germany; cat no: 81156) and exposed
to 100 µM and 300 µM tolbutamide (Sigma-Aldrich Corp.;
cat no: T0891) and metformin (as a gift from Bilim İlaç
San. ve Tic. A.Ş., Kocaeli, Turkey) for 24 h. The images
holographic of the cells were captured randomly by
HoloMonitor M4 instrument (Phase Holographic Imaging
PHI AB, Lund, Sweden) at 1 h and 24 h. Alteration of the
cell morphology was analyzed by HoloStudio 2.4 software
(Phase Holographic Imaging PHI AB).

2.1. In silico study
Connectivity map database (Lamb et al., 2006; Jun et
al., 2017) was used to search the correlation between
oral antidiabetic drugs and Rho kinase inhibitors. In
connectivity map we used the touchstone tool which
contains expression profiles of a variety of cell lines-treated
with thousands of chemicals. We researched metformin
and tolbutamide separately in the touchstone tool. When
we detailed the list about correlation score, we chose Rho
kinase inhibitors against metformin and tolbutamide.
A positive connectivity score indicated that there is a
similarity among the expression levels of genes induced
by small molecules. In general, in order to have a strong
hypothesis, the score should be 90 and above. From the list
obtained, the high scores obtained in eight cell lines of Rho
kinase inhibitor fasudil and ripasudil were selected. All the
data obtained from CMAP were found at Broad Institute1.
2.2. Cell culture
Human breast cancer MCF-7 obtained from ATCC and
human cervical cancer HeLa obtained from Şap Institute
(Ankara, Turkey) cell lines were used in this study. The
cells were grown in DMEM (Dulbecco’s modified eagle
medium) (Sigma-Aldrich Corp., St. Louis, MO, USA; cat
no: D6429), containing 10 % fetal bovine serum (SigmaAldrich Corp.; cat no: F9664), 100 U/mL penicillin and
100 µg/mL streptomycin (Capricorn Scientific GmbH,
Ebsdorfergrund, Germany; cat no: PS-B) at 37 °C. When
Broad Institute (2020). Connectivity Map 02 [online]. Website
http://www.broad.mit.edu/cmap/ [accessed 00 Month Year].
1
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2.3. xCelligence assay
The xCELLigence system real-time cell analyzer was
used for the determination of nontoxic concentrations of
metformin and tolbutamide (Özdemir and Ark, 2013).
Briefly, this system measures electronic impedance
through microelectrodes placed on the surface of special
16-well plate called e-plate. After the cells are seeded on
these special plates, as the attached cell number increases,
the electronic impedance increases.
10,000 cells were plated on e-plates and monitored
every 15 min for 24 h. After 24 h attachment, the media
was replaced with fresh media. Then cells were exposed
to metformin and tolbutamide at indicated concentrations
for another 24 h. Since there was a solubility problem
at concentrations above 300 µmol, we tested drugs with
concentrations starting at 300 µmol and decreasing
logarithmically. The slopes of the curves were calculated
using the software of the xCELLigence RTCA DP system
as an indicator of cell proliferation.

2.5. Activation determination of cofilin (phospho-Ser3)
Phosphorylation of cofilin was performed using
phospho-cofilin (Ser3) colorimetric cell-based ELISA
kit (Aviva Systems Biology Corp., San Diego, CA, USA;
cat no: OKAG01911) according to the manufacturer’s
instructions (Şimay et al., 2018). Ten thousand HeLa and
MCF-7 cells were seeded to each well of the kit. Then, the
next day, the cells were incubated with metformin and
tolbutamide for 1 h. The cells were then fixed for 20 min
at room temperature. After washing the plate with wash
buffer three times, blocking buffer was added to each well
and the plate was incubated for 1 h at room temperature.
The plate was washed three times. Then antibodies for the
target antigen (cofilin, phospho-cofilin, GAPDH) were
added to each well and cells were incubated for 16 h at 4 °C.
After each well was washed, the cells were incubated with
HRP-conjugated secondary antibodies for 2 h at room
temperature with gentle shaking. Following washing the
plate three times, TMB substrate was added and the plate
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was incubated for 30 min at room temperature. Then the
stop solution was added to each well. The absorbance of
each well was read at 450 nm immediately.
2.6. Statistical analysis
All the values were assessed using one way ANOVA test
followed by Tukey’s post hoc test to analyze multiple group
comparison using GraphPad Prism version 6.0 (GraphPad
Software Inc., La Jolla, CA, USA). Statistical significance
was set at P ≤ 0.05.
3. Results
3.1. Analysis of ROCK inhibitor candidates using connectivity map
To explore whether metformin and tolbutamide have a
possible inhibitor effect on Rho kinase, we utilized the
CMAP by comparing the changes in gene expression
between metformin and tolbutamide, and various Rho
kinase enzyme inhibitors. The scores in individual cell lines
are given in Table. Our analysis showed that metformin
was similar to fasudil with a score of 99.79 in MCF-7 cells
and tolbutamide was similar to GSK-429286A with a score
of 96.54 in HCC515. This analysis suggests that metformin
and tolbutamide might be a potential Rho kinase inhibitor.
3.2. Effect of tolbutamide and metformin on cell proliferation
To evaluate the effect of metformin and tolbutamide
on cell proliferation, we treated cells with different
concentrations of drugs and cells were monitored for 24 h.
Our results showed that none of the tested concentrations
of metformin and tolbutamide had no effect on cell
proliferation (Figure 1). Thus we used nontoxic high
concentrations of metformin and tolbutamide for their
possible inhibitor effect on Rho kinase.
3.3. Effect of tolbutamide and metformin on morphology of cells
The possible effect of tolbutamide and metformin on cell
morphology was assessed by a holographic microscope in
HeLa and MCF-7 cells. Four morphological parameters,
including cell area, cell volume, average thickness, and
cell shape irregularities were calculated from the images
obtained by a holographic microscope. One day after the
cells were seeded, the cells were maintained with serum
free DMEM for 24 h. Then the cells were exposed to

tolbutamide and metformin, and the images were captured
at 1 h and 24 h.
The measurements demonstrated that while 300 µM
tolbutamide, 100 µM and 300 µM metformin decreased
the cell area compared to the control group at 1 h (Figure
2), only incubation of 300 µM metformin for 24 h resulted
in the decrease of the cell area in HeLa cells (Figure 3).
In other morphological changes, only cell irregularity
after the treatment of tolbutamide at 1h was increased
significantly (Figure 2).
In MCF-7 cells, tolbutamide and metformin at all the
concentrations at 1 h reduced the cell area significantly
compared to the control (Figure 4). Additionally 300 µM
tolbutamide and metformin decreased the cell area with
24-hour incubation (Figure 5). Interestingly, treatment of
300 µM tolbutamide, 100 µM and 300 µM metformin 300
for 24 h resulted in a significant reduction in cell volume
in MCF-7 cells (Figure 5).
3.4. Effect of tolbutamide and metformin on the activation of ROCK
ROCK has many downstream effectors that are involved in
cytoskeleton dynamics, such as MLC phosphatase, MLC,
ERM and LIM kinase (Riento and Ridley, 2003). LIM
kinase-described one of the substrates is cofilin family of
actin-binding proteins, an actin-depolymerizing factor.
Once ROCK is activated, it phosphorylates concomitantly
activates LIM kinase. Then LIM kinase phosphorylates
cofilin at serine 3 and inactivates the protein.
To determine whether tolbutamide and metformin
inhibit the activation of ROCK, we used phospho-cofilin
(Ser3) colorimetric cell-based ELISA kit. HeLa and MCF7 cells were seeded in 96-well plates. The next day, medium
of the cells was replaced with serum free DMEM. After 24 h,
the cells were incubated with an appropriate concentration
of tolbutamide and metformin for 1 h. Then, according to
the manufacturer’s instructions, ELISA kit was performed.
We showed that 100 µM metformin increased the cofilin
phosphorylation in HeLa cells (Figure 6A). However,
while 100 µM tolbutamide increased the phosphorylation
of cofilin, both concentrations of metformin decreased
the phosphorylation of cofilin significantly in MCF-7 cells
(Figure 6B) suggesting that metformin suppresses the
activation of ROCK.

Table. Comparison of metformin with fasudil and tolbutamide with GSK-429286A in the level of gene expression in cell
lines using connectivity map.
Summary MCF-7 A375 A549

HCC515 HT29 PC3

HA1E VCAP

87.39

99.79

52.55 50.29

78.64

88.82

88.43

66.65

84.98

Tolbutamide vs. GSK-429286A score 53.62

11.41

80.54 44.22

96.54

85.40

-23.63 73.72

25.55

Metformin vs. fasudil score
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Figure 1. Monitoring of cell proliferation after the treatment of tolbutamide and metformin using the xCELLigence system. A. An
original trace of tolbutamide- and metformin-treated HeLa cells recorded by RTCA DP instrument (In tolbutamide-treated trace,
cyan curve: control, pink curve: 10 µM tolbutamide, blue curve: 30 µM tolbutamide, green curve: 100 µM tolbutamide, red curve: 300
µM tolbutamide) (In metformin-treated trace, red curve: control, cyan curve: 10 µM metformin, pink curve: 30 µM metformin, blue
curve: 100 µM metformin, green curve: 300 µM metformin). B. An original trace of tolbutamide- and metformin-treated MCF-7 cells
recorded by RTCA DP instrument (In tolbutamide-treated trace, red curve: control, pink curve: 10 µM tolbutamide, cyan curve: 30
µM tolbutamide, green curve: 100 µM tolbutamide, blue curve: 300 µM tolbutamide) (In metformin-treated trace, green curve: control,
cyan curve: 10 µM metformin, pink curve: 30 µM metformin, blue curve: 100 µM metformin, red curve: 300 µM metformin). C. Slope
of the curves in (A) as an index of the cell attachment rate. D. Slope of the curves in (B) as an index of the cell attachment rate. Data are
means ± sem from 3 determinations.

38

ÖZDEMİR and ARK / Turk J Biol

Figure 2. Investigation of HeLa cells morphology with Holomonitor M4 after 1 h drug incubation. A. Representative 3D pictures
of HeLa cells treated with tolbutamide and metformin for 1 h. a: control, b: 100 μM tolbutamide, c: 100 μM metformin, d: 300 μM
tolbutamide, e: 300 μM metformin. B. Statistical analysis of cell area, cell volume, average thickness, and irregular parameters in the form
of cells. Cont: Control, 100 µM Tol: 100 µM Tolbutamide, 300 µM Tol: 300 µM Tolbutamide, 100 µM Met: 100 µM Metformin, 300 µM
Met: 300 µM Metformin. * shows significant difference from the control group (one-way ANOVA, Tukey, P ≤ 0.05, n = 3).
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Figure 3. Investigation of HeLa cells morphology with HoloMonitor M4 after 24 h drug incubation. A. Representative 3D pictures
of HeLa cells treated with tolbutamide and metformin for 24 h. a: control, b: 100 μM tolbutamide, c: 100 μM metformin, d: 300 μM
tolbutamide, e: 300 μM metformin. B. Statistical analysis of cell area, cell volume, average thickness, and irregular parameters in the form
of cells. Cont: Control, 100 µM Tol: 100 µM Tolbutamide, 300 µM Tol: 300 µM Tolbutamide, 100 µM Met: 100 µM Metformin, 300 µM
Met: 300 µM Metformin. * shows significant difference from the control group (one-way ANOVA, Tukey, P ≤ 0.05, n = 3).
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Figure 4. Investigation of MCF-7 cells morphology with HoloMonitor M4 after 1 h drug incubation. A. Representative 3D pictures
of MCF-7 cells treated with tolbutamide and metformin for 1 h. a: control, b: 100 μM tolbutamide, c: 100 μM metformin, d: 300 μM
tolbutamide, e: 300 μM metformin. B. Statistical analysis of cell area, cell volume, average thickness, and irregular parameters in the
form of cells. Cont: Control, 100 µM Tol: 100 µM Tolbutamide, 300 µM Tol: 300 µM Tolbutamide, 100 µM Met: 100 µM Metformin, 300
µM Met: 300 µM Metformin. * shows significant difference from the control group (one-way ANOVA, Tukey, P ≤ 0.05, n = 3).
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Figure 5. Investigation of MCF-7 cells morphology with HoloMonitor M4 after 24 h drug incubation. A. Representative 3D pictures
of MCF-7 cells treated with tolbutamide and metformin for 24 h. a: control, b: 100 μM tolbutamide, c: 100 μM metformin, d: 300 μM
tolbutamide, e: 300 μM metformin. B. Statistical analysis of cell area, cell volume, average thickness, and irregular parameters in the form
of cells. Cont: Control, 100 µM Tol: 100 µM Tolbutamide, 300 µM Tol: 300 µM Tolbutamide, 100 µM Met: 100 µM Metformin, 300 µM
Met: 300 µM Metformin. * shows significant difference from the control group (one-way ANOVA, Tukey, P ≤ 0.05, n = 3).

42

ÖZDEMİR and ARK / Turk J Biol

Figure 6. Determination of activation of Rho Kinase through the cofilin phosphorylation.
A. Determination of cofilin phosphorylation in HeLa cells after 24-h drug incubation. B.
Determination of cofilin phosphorylation in MCF-7 cells after 24-h drug incubation. * shows
significant difference from the control group (one-way ANOVA, Tukey, P ≤ 0.05, n = 3).

4. Discussion
Many drug molecules show their therapeutic effects
through their specific targets. In addition to their primary
targets, these drugs may also show an affinity for other
unexpected off-target molecules (Tang et al., 2018). With
the interaction of drugs and off-targets, the toxic effects
of drugs can occur. Apart from the toxic effect, this
undesirable interaction turns into an advantage in some
cases. Defining off-target potencies of approved drugs
enables the use of these drugs in various pathological
conditions.
Apart from the effects of metformin in diabetes
treatment, it also has beneficial effects in different
physiopathologies. There are several data supporting that
metformin is thought to be a promising agent for single
use or chemotherapy combinations in cancer treatment.
Metformin directly contributes to cancer treatment
through upregulating miR-26 resulting in the inhibition
of cell migration and invasion, and through the induction

of apoptosis in some cancer cell lines (Li et al., 2012; Bao
et al., 2012). These findings suggest that oral antidiabetics,
especially metformin, may also be effective in different
pathological conditions.
In this study, it was determined that metformin and
tolbutamide, which are used in the treatment of type
II diabetes, may cause inhibition of Rho kinase using
connectivity map program. In order to confirm this data,
MCF-7 and HeLa cells were exposed to these two small
molecules, and the effects of these compounds on the
morphological changes occurring as a result of Rho kinase
activation and phosphorylation of cofilin were assessed.
ROCK has many substrates that are involved in the
control of rearrangements of actin and microtubule
cytoskeletons resulting in changes in cell morphology.
Many studies indicated that inhibition of Rho kinase
induced drastic alterations in cell shape. Previously we
showed that pretreatment of Rock inhibitor, Y-27632,
significantly reduced the increased cell area induced by
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cardiac glycosides in HeLa cells (Şimay et al., 2018). Zhang
et al. (2011) demonstrated that treatment of both Y-27632
and HA-1077 resulted in changes in cell morphology
inducing the formation of large numbers of protrusions
in HOB and Saos-2 (Zhang et al., 2011). Therefore,
metformin and tolbutamide were applied to the cells to
examine the possible morphological change that drugs
could induce through the inhibition of Rho kinase. We
found that while metformin and tolbutamide reduced the
cell area at 1h in HeLa and MCF-7 cells, only treatment of
metformin resulted in a reduction of cell area at 24 h. This
reduction in cell morphology pointed out that especially
metformin may cause Rho kinase inhibition.
Activation of LIM kinase, one of the Rho kinase
substrates, occurs as a result of Rho kinase activation.
LIM kinases control cytoskeleton dynamics through the
phosphorylation of the cofilin family proteins. When
cofilin is phosphorylated by LIMK, it is inactive. To
examine whether tolbutamide and metformin would
cause inhibition of Rho kinase and whether the reduction
in cell area would be accompanied by Rho kinase, the
phosphorylation of cofilin was evaluated. In MCF-7
cell, metformin treatment significantly reduced cofilin
phosphorylation compared to the control group indicating
that metformin inhibits ROCK activation. These results
suggested that metformin can inhibit Rho kinase in a cell
type-dependent manner.
Although our findings suggest that metformin might
be a ROCK inhibitor, whether this inhibition occurs

directly from the interaction of ROCK and metformin
directly has not been shown.
There are major signaling pathways that regulate
cytoskeletal properties thereby cell morphology such as
PI3 kinase‒Akt and Rho‒ROCK pathway (Amano et al.,
2010; Jo et al., 2014; Moujaber and Stochaj, 2020). The
reduction in cell area after the treatment of MCF-7 cells
with tolbutamide for 24 h gave the clue that tolbutamide
might inhibit ROCK. However, when we evaluated the
activation of Rho kinase after tolbutamide treatment, we
showed that tolbutamide had no effect on ROCK activation
suggesting that the decrease in cell area occurs in a Rho
kinase-independent manner. These data suggest that
tolbutamide might affect cell morphology through another
pathway involved in actin cytoskeleton organization such
as the PI3 kinase‒Akt pathway.
In conclusion, our results enabled metformin to be
identified as a new and approved inhibitor of ROCK. It
also suggested that especially metformin that is approved
by FDA might be used for the treatment in various
pathological conditions in where Rho kinase is involved
such as asthma, cancer, erectile dysfunction, glaucoma.
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